BrainsWay Announces The Publication Of Feasibility Clinical Data Evaluating The Analgesic Effects Of Deep Transcranial Magnetic Stimulation In Patients With Peripheral Neuropathic Pain. The Results Were Published In The Neuromodulation Journal, In A...
BrainsWay Announces The Publication Of Feasibility Clinical Data Evaluating The Analgesic Effects Of Deep Transcranial Magnetic Stimulation In Patients With Peripheral Neuropathic Pain. The Results Were Published In The Neuromodulation Journal, In A...
BrainsWay Announces The Publication Of Feasibility Clinical Data Evaluating The Analgesic Effects Of Deep Transcranial Magnetic Stimulation In Patients With Peripheral Neuropathic Pain. The Results Were Published In The Neuromodulation Journal, In A Peer-Reviewed Article Entitled, "H-Coil Repetitive Transcranial Magnetic Stimulation Relieves Pain And Symptoms Of Anxiety And Depression In Patients With Chronic Peripheral Neuropathic Pain: A Randomized Sham-Controlled Crossover Study."
BrainsWay宣佈發表了一項可行性臨床數據評估，研究了深部經顱磁刺激對患有外周神經病性疼痛的患者的鎮痛效果。結果已發表在《神經調控雜誌》上，題爲「H-線圈重複經顱磁刺激緩解慢性外周神經病性疼痛患者的疼痛和焦慮抑鬱症狀：一項隨機安慰劑對照交叉研究」中。
BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the publication of positive feasibility clinical data evaluating the analgesic effects of deep transcranial magnetic stimulation (Deep TMS) in patients with peripheral neuropathic pain. The results were published in the Neuromodulation journal, in a peer-reviewed article entitled, "H-Coil Repetitive Transcranial Magnetic Stimulation Relieves Pain and Symptoms of Anxiety and Depression in Patients with Chronic Peripheral Neuropathic Pain: A Randomized Sham-Controlled Crossover Study."
BrainsWay股份有限公司（納斯達克和以色列證券交易所：BWAY）（「BrainsWay」或「公司」），全球領先的先進非侵入性神經刺激治療技術的領導者，今天宣佈發表了評估深部經顱磁刺激（Deep TMS）對患有外周神經病性疼痛的患者的鎮痛效果的積極可行性臨床數據。結果已發表在《神經調控雜誌》上，題爲「H-線圈重複經顱磁刺激緩解慢性外周神經病性疼痛患者的疼痛和焦慮抑鬱症狀：一項隨機安慰劑對照交叉研究」中。
The double-blind, randomized crossover trial included seventeen (17) patients with chronic neuropathic pain. Participants were assigned to either an active Deep TMS or sham treatment arm for a five-day period, followed by a nine-week washout, before crossing over to the other arm. The study's primary outcome measure was a comparison between the patterns of the active and sham groups' self-reported changes in pain levels from baseline. Secondary outcomes included changes in pain ratings at specific time points in the two arms, as well as changes in comorbid symptoms experienced by the patients, including, for example, anxiety and depression.
這項雙盲、隨機交叉試驗包括十七（17）名慢性神經病性疼痛患者。參與者被分配到爲期五天的積極Deep TMS或安慰劑治療組，隨後進行九周停藥期，然後交叉到另一個治療組。研究的主要結果指標是積極組和安慰劑組基線下疼痛水平的自我報告變化模式的比較。次要結果包括兩個治療組在特定時間點的疼痛評分變化，以及患者經歷的共患症狀變化，例如焦慮和抑鬱。
Results showed that Active deep-TMS therapy significantly reduced "usual pain intensity" in patients with chronic peripheral neuropathic pain compared to sham treatment and improved symptoms of anxiety and depression in the same patient population.
結果顯示，積極的深部TMS療法顯著降低了慢性外周神經病性疼痛患者的「一般性疼痛強度」，與安慰劑治療相比，並改善了同一患者群體的焦慮和抑鬱症狀。
譯文內容由第三人軟體翻譯。
